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Abstract
Background: Wheezing disorders in childhood vary widely in clinical presentation and disease course. During the last years,
several ways to classify wheezing children into different disease phenotypes have been proposed and are increasingly used
for clinical guidance, but validation of these hypothetical entities is difficult.
Methodology/Principal Findings: The aim of this study was to develop a testable disease model which reflects the full
spectrum of wheezing illness in preschool children. We performed a qualitative study among a panel of 7 experienced
clinicians from 4 European countries working in primary, secondary and tertiary paediatric care. In a series of questionnaire
surveys and structured discussions, we found a general consensus that preschool wheezing disorders consist of several
phenotypes, with a great heterogeneity of specific disease concepts between clinicians. Initially, 24 disease entities were
described among the 7 physicians. In structured discussions, these could be narrowed down to three entities which were
linked to proposed mechanisms: a) allergic wheeze, b) non-allergic wheeze due to structural airway narrowing and c) non-
allergic wheeze due to increased immune response to viral infections. This disease model will serve to create an artificial
dataset that allows the validation of data-driven multidimensional methods, such as cluster analysis, which have been
proposed for identification of wheezing phenotypes in children.
Conclusions/Significance: While there appears to be wide agreement among clinicians that wheezing disorders consist of
several diseases, there is less agreement regarding their number and nature. A great diversity of disease concepts exist but a
unified phenotype classification reflecting underlying disease mechanisms is lacking. We propose a disease model which
may help guide future research so that proposed mechanisms are measured at the right time and their role in disease
heterogeneity can be studied.
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Introduction
Wheezing disorders in childhood are common and vary widely
in clinical presentation and disease course (onset, remission and
relapse). Within this syndrome, various phenotypes have been
proposed, classified either by triggers of wheeze, into ‘‘episodic
viral wheeze’’ triggered only by colds and ‘‘multiple-trigger
wheeze’’ triggered also by other factors [1,2,3], or by time course
into ‘‘early transient’’, ‘‘persistent’’ and ‘‘late-onset’’ wheeze [4,5].
Such phenotypes are being used in the study of risk factors
[4,6,7,8,9], prognosis [10,11,12,13] and response to treatment
[2,14,15], and also increasingly in treatment recommendations
and guidelines [2,16,17]. However it is unclear whether they
represent distinct disease entities with separate aetiologies or rather
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mechanisms are poorly understood it is difficult to define a
biologically plausible classification of wheezing disorders.
Recently a ‘‘hypothesis-free’’ approach to define phenotypes has
been explored [18,19,20,21,22]. This approach uses multivariate
methods such as cluster analysis applied to a wide range of
observed features including symptoms, signs or physiological
measurements, in order to identify disease groups that might better
reflect underlying biological pathways. These methods have
yielded clusters (i.e. phenotypes) that are compatible with previous
proposed phenotypes [19,20]. However, clustering methods may
distinguish groups regardless of whether they exist in the
population as true entities or not. It is therefore essential to
validate the output of these methods, i.e. to test whether the
methods can distinguish between a homogenous and heteroge-
neous population, and whether they can identify the true disease
entities existing within a heterogeneous population. Such a
validation can, for instance, be done by artificially creating a
heterogeneous population consisting of known disease entities and
then applying the clustering method to data from this population
to see whether the method can detect the heterogeneity and
recover the true entities. This however requires a plausible model
of disease consisting of predefined disease entities.
This study describes the creation of a plausible model of
wheezing diseases in children, consisting of distinct hypothetical
disease entities which would help in the validation of ‘‘hypothesis-
free’’ methods. In order to obtain a disease model, we set up a
small panel of clinicians familiar with paediatric wheezing
disorders to agree on a set of disease entities for wheezing in
preschool children based on their clinical experience.
We report here the qualitative part of this study which aimed to
collect the initial views of the clinicians in the panel regarding the
classification of wheezing disorders and, subsequently, to create a
disease model by consent through structured discussions.
Methods
Selection of the Panel
The core group (authors BS, MS and CK) invited 9 clinicians
from 4 countries Switzerland (CH), Austria (AT), the Netherlands
(NL) and the UK of whom 7 participated (CH 2 participants, AT
1, NL 2, UK 2). These were selected from contacts known to
members of the core group or brought to their attention through
colleagues. All were clinicians working in primary care or
paediatric pulmonology, who have seen many preschool children
with wheeze, and whose individual views on asthma phenotypes
were not previously known to the core group. The panel size was
kept small enough to allow structured telephone discussions
between members.
Collecting Initial Views
The panel members were sent a questionnaire containing three
questions. First, panel members were asked which view they most
agreed with: (a) wheezing disorders in preschool children form a
single, though highly variable, disease entity, (b) wheezing
disorders in preschool children consist of different disease entities,
or (c) undecided. In this context, a disease entity was defined as a
wheezing disorder affecting a group of children which was distinct
in aetiology from other wheezing disorders in other groups. The
population of interest was defined as 0–5 year olds from the
general population who are brought to a general practitioner with
wheeze as a major symptom, and in whom wheeze caused by
specific conditions such as cystic fibrosis, bronchopulmonary
malformations or foreign body aspiration had been excluded.
Second, respondents consenting to view (b) (above) were asked
how many disease entities they thought existed, and third, for each
of these entities, they were asked to provide a descriptive label and
a bullet-point description of symptom patterns, physiological
features, possible mechanisms, natural history and response to
treatments.
The core group extracted the descriptive information on the
proposed disease entities into tabular format. For this, feature
categories (such as ‘‘shortness of breath’’ or ‘‘activities limited’’)
were formed based on the descriptions of all proposed entities. For
each of the disease entities the table contained a feature profile
with the entry ‘1’ if a particular feature was mentioned and ‘0’ if
not. Using multiple correspondence analysis (MCA) [23], these
feature profiles were graphically displayed in a plane representing
the two main dimensions of variability. In this representation,
points lying close together represent entities with similar feature
profiles.
Agreement on a Disease Model
The core group defined an initial model consisting of disease
entities that had been proposed in a similar form by at least two
respondents. The entities were described using a synthesis of the
original bullet point descriptions by panel members. The panel
was asked to propose and discuss changes to this model and agree
on a final set of disease entities that could be justified by distinct
pathophysiological mechanisms. These discussions were conduct-
ed by conference calls followed by e-mail correspondence. The
phone conferences were recorded, abstracted and summarised to
inform all panel members and for later reference.
Results
Initial Views and Propositions
Among the 7 respondents to the initial invitation, 6 held the
view that these disorders consist of different disease entities, while
one was undecided. Each of the 6 independently proposed and
described 2–5 disease entities for classifying childhood wheezing
disorders, amounting to an initial total of 24 disease entities
(Table 1, Figure 1). MCA of the feature profiles showed that when
different panel members suggested similar labels they also gave a
similar description of the corresponding entities (Figure 1). For
instance, among the 6 panel members subscribing to the multiple-
disease view, all proposed an entity corresponding to wheeze
associated with allergy or multiple triggers. These entities lie
clustered together on the positive side of the main axis, axis 1,
identified by MCA (Figure 1, ellipse on the right). Similarly, these
members each suggested an entity corresponding to virus-induced
(exclusive viral) wheeze with no other triggers (Figure 1, ellipse on
the bottom left). Furthermore, two members suggested entities
involving structural narrowing of airways because of maternal
smoking during pregnancy, and two members suggested an entity
comprising children born preterm. As a basis for further
discussion, the core team therefore suggested an initial disease
model consisting of these four entities using the labels: (i) allergic/
multiple-trigger wheeze, (ii) exclusive viral wheeze, (iii) airway
narrowing as a consequence of a developmental process, and (iv)
ex-preterms.
Discussions and Agreement on a Disease Model
There was general agreement among members that an
allergic form of wheeze associated with interval symptoms
should be distinguished from wheeze occurring only during viral
infections, i.e. (i) and (ii). The panel members also agreed that
the entities (iii) and (iv) might be subsumed to a single entity,
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major cause for viral wheeze in this age group. Both smoking
during pregnancy and pre-maturity could be regarded as
predisposing factors for airway narrowing and should not define
separate disease entities.
There was a consensus that atopy and structural airway
narrowing represented two mechanisms of current wheezing.
Proposing further mechanisms and phenotypic features that would
distinguish these from other mechanisms was perceived as highly
speculative for the following reasons.
1. Although triggers are commonly used to distinguish pheno-
types, they may not be specific for individual mechanisms. For
instance, wheeze occurring only during viral infections may be
due to structurally narrow airways. However, almost all wheezy
children in this age group have symptoms during viral
infections, suggesting that other mechanisms are involved.
2. There is a lack of feasible measurements in this age group that
would distinguish children with different outcomes in later
childhood. For instance, in the first few years of life, children
who later develop allergic wheeze are clinically very similar to
children who only wheeze during viral infections. One can only
speculate whether the mechanisms for viral wheeze in these
two groups differ.
3. It is unclear to what extent this age group is also affected by
non-allergic, multiple-trigger wheeze that might be indicative
of different mechanisms.
However, for the purpose of this study, the panel members
agreed on a final set of 3 entities (Table 2) that plausibly explain
the observed heterogeneity of childhood wheezing disorders:
Allergic wheeze, non-allergic wheeze due to structural airway
narrowing and non-allergic wheeze due to increased immune
response to viral infections. These entities represented three
mechanisms that could contribute to recurrent wheezing diseases
in young children.
Although there was some disagreement concerning acute viral
bronchiolitis, panel members agreed that none of the other entities
they had originally proposed should be considered as separate
disease entities. The consensus was, that some of them represented
wheezing secondary to underlying conditions with clear diagnoses
(7, 19, 20 in Table 1), while others were limited to particular
exposures (15), were poorly defined and outdated (9) or were a
general sign of inflammation (22).
Discussion
In this study we aimed to agree on a disease model for wheezing
disorders in young children consisting of distinct disease entities
each based on plausible mechanisms. We wanted this model to be
developed and agreed upon by clinicians who encounter the full
range of clinical presentations of these disorders, working in
primary, secondary, and tertiary care. The model is the first step in
a validation study of statistical methods used to identify subgroups
of disease from epidemiological data.
Table 1. Classification of wheezing disorders in children aged 0-5 years as initially suggested by panel members.
Panel member Disease entity nr Descriptive label
1 1 Wheeze caused by tobacco smoke exposure (pre- or postnatal)
2 Wheeze caused by viral and bacterial infections
3 Allergic asthma
4 Wheeze in ex-prematures
2 5 Airway narrowing as a consequence of an intrauterine process (smoking during pregnancy)
6 Allergic (eosinophilic) asthma
7 Acute viral bronchiolitis (in the first year of life)
8 Viral induced bronchitis
9 Happy wheezer
3 10 Episodic viral wheeze
11 Multiple-trigger wheeze
4 12 Allergic wheeze (IgE mediated)
13 Non-allergic asthma
14 Infective wheeze
15 Irritant exposure wheeze
16 Exercise-induced wheeze
5 17 Virus-induced wheeze
18 Atopic asthma
19 Persistent wheeze (daily symptoms of wheeze; structural causes/malacia)
20 Wheeze secondary to underlying condition
21 Wheeze in ex-prematures, small airways
6 22 Wheeze associated with bronchial secretions
23 Viral wheeze, episodic to persistent
24 Viral wheeze associated with atopic disposition
7 - Undecided
doi:10.1371/journal.pone.0008533.t001
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First, we found that the majority of clinicians (6/7 in our
sample) supported the view that wheezing disorders in preschool
children consist of several different disease entities. Second, we
found a broad range of concepts and definitions for different forms
of childhood wheeze. Among the disease entities proposed by the 6
panel members subscribing to a multiple-disease view, only a few
entities were similar across two or more physicians, the best
agreement being found for the two entities described as ‘‘allergic
wheeze associated with interval symptoms’’ and ‘‘exclusive viral
wheeze occurring only during viral infections’’. There was no
agreement among panel members on the potential number of
disease entities. Third, clinicians’ concepts of disease mechanisms
underlying wheezing disorders were vague. Except for allergic
wheeze, which represents the classical asthma phenotype, all panel
members were reluctant to define entities in terms of explicit
mechanisms, and perceived this task as highly speculative. Fourth,
it became clear that the clinical information that might be used to
distinguish different mechanisms is limited in early childhood. For
instance, non-viral triggers that may be important in later years
are less relevant (aeroallergens) or cannot be assessed (exercise) in
early childhood. Also, the possibilities for physiological measure-
ments are restricted in the first few years of life.
Comparison with Literature
To our knowledge, this is the first study describing current views
of clinicians on phenotypes of wheeze in preschool children, and
the first which has tried to obtain a consensus among them in
order to propose a disease model. The final model proposed by the
panel, and the main mechanisms suggested reflect current
discussions in the literature.
Allergy. Allergic sensitisation is associated with persistent
wheeze in childhood but not with early transient wheeze [24,25].
There is evidence that allergic sensitisation can begin in infancy, in
particular sensitisation to food allergens [26,27,28], however,
incidence increases markedly after the age of 2–3 years mainly due
to sensitisation to aeroallergens [26]. In children who develop
atopic asthma onset of sensitisation tends to be early [29].
Structurally narrow airways. Evidence suggests that poor
lungfunctionininfancyisassociatedwithsubsequentearlychildhood
Figure 1. Graphical display of disease entities initially suggested by panel members. The figure shows the position of disease entities
initially suggested by panel members along the two main axes of variability identified by multiple correspondence analysis. The position of each
entity is determined by its feature profile (features used by the panel member to describe the entity) such that entities with similar features lie close
together. The numbering follows that used in table 1 and entities suggested by the same panel member are coloured with the same colour. The
ellipses indicate groups of entities which have similar label names but were suggested independently by different panel members. The fact that
entities within the same ellipse lie close to each other indicates that when different panel members suggested similar labels they also gave a similar
description of the corresponding entities. The initial disease model consisted of 4 entities representing the 4 ellipses.
doi:10.1371/journal.pone.0008533.g001
A Model for Childhood Wheezing
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8533wheezing [4,30]. Flow limitation can be caused by decreased airway
dimensions and/or altered airway wall mechanics [31]. Factors that
can lead to such changes in airway structure and/or function include
maternal smoking during pregnancy [32] or preterm birth, even in
the absence of neonatal respiratory disease [33,34].
Increased immune responsiveness to viral infections.
Wheeze in infancy is predominantly triggered by viral infections
[35]. The majority of children experience respiratory viral
infections in the first years of life and responses vary widely from
asymptomatic disease in some children, through mild upper
respiratory illness in many to severe lower respiratory disease in a
minority of infants [36]. Host specific factors associated with the
severity of this response include mechanical and immunologic
factors such as an imbalance between Th1 and Th2 type responses
[37,38].
The disease model proposed by the panel of clinicians is
therefore not novel with respect to the hypothesised mechanisms.
It is however original in the selection of these particular
mechanisms as the main sources of heterogeneity in preschool
wheezing disorders. Other expert-driven attempts to distinguish
phenotypes of wheeze have mainly been based on long-term
temporal patterns (early transient, persistent and late onset
wheeze) [4,5] or main triggers (viral wheeze, multiple-trigger
wheeze) [1,2,3].
Strengths and Limitations of Our Approach
Our approach brought together a wide range of initial views and
concepts from clinicians who encounter the full clinical spectrum of
wheezing disorders in young children. The panel was heterogenous,
composed of physicians from four different countries, including
both paediatric pulmonologists and general practitioners, yet small
enough to allow a co-ordinated discussion and an agreement on a
final disease model. We included people who have a broad clinical
experience and research interests, butwho hadnot been performing
research on phenotypes of childhood wheeze nor were closely
relatedto a group whichhad done this. Therefore, ourresults reflect
a broad range of different opinions from specialists and generalists
across different European countries.
Limitations of this study include small sample size and reliance
on subjective views of individuals. Clearly, sample size is too small
to represent the full spectrum of views amongst clinicians at large,
and we cannot know the extent to which the list of initially
proposed disease concepts is exhaustive. Thus, inclusion of more
clinicians might have resulted in more initial disease entities, and
perhaps in a different final disease model. However, our study did
not aim to obtain a representative consensus view for the wider
population of clinicians; rather it was an attempt to generate
hypotheses for further research and discussion. Also, our
conclusions are not based on objective data, but on the subjective
views of clinicians. Clinician’s perceptions represent a synthesis of
information from a wide range of sources including first hand
clinical observations, but also published literature. We wanted to
combine this information to generate a model for wheezing
disease. The study was designed as a qualitative and exploratory
study and not as a confirmatory study that would require large
samples of preferably objective data.
Table 2. Disease model for wheezing disorders in children aged 0–5 years as agreed by panel.
Descriptive
label A) Allergic wheeze
B) Non-allergic wheeze due to
structural airway narrowing
C) Non-allergic wheeze due to
increased immune response to
viral infections
Symptoms
and triggers
Symptoms Wheeze, cough, breathlessness, nocturnal
cough
Wheeze, cough, breathlessness Wheeze, cough, breathlessness
Symptom
pattern
Episodic, often with interval symptoms;
severity and duration of episodes highly
variable; perennial
Episodic; episodes short (,2 wks)
and variable in severity; occurring
mainly during the cold season
Episodic; episodes short (,2 wks) and
variable in severity; occurring mainly
during the cold season
Potential
triggers
Viral infections, allergens, ETS, pollution Mainly viral infections, ETS,
possibly exercise
Viral infections only
Physiological
features
Lung function,
reactivity
Normal LF when well controlled, decreased
otherwise; chronically reduced in persistent
severe asthma; positive BDR; BHR
Reduced LF; BHR Reduced LF during exacerbations,
normal if symptom-free; BDR positive
only during exacerbations
SPT Positive (aeroallergens) Negative Negative
Other Increased exhaled NO; eosinophils (BAL);
airway remodelling (biopsy)
Normal exhaled NO; neutrophils
(BAL)
Normal exhaled NO; neutrophils (BAL)
Aetiology Mechanisms Allergic inflammation in combination with
other causes of increased responsiveness
to viral infections
Congenital narrowing of airways
causing increased responsiveness
to viral infections
Increased immune responsiveness to
viral infections not related to atopy;
possibly a maturational defect
Risk factors Parental atopy or asthma (strong genetic
component), high exposure to allergens and
high frequency of viral infections in early life
Smoking during pregnancy,
premature birth, genetic
predisposition
Genetic predisposition, premature
birth, increased frequency of viral
infections
Natural history Onset Atopic predisposition at birth; early
onset; non-viral triggers usually .4 yrs
In infancy 0–3 years
Persistence
and prognosis
Tends to persist into adolescence and
adulthood; can lead to irreversible
airway obstruction
Tendency to remit by 5 years;
relapse and/or reduced lung
function in later life possible
Tendency to remit by 5 years;
relapse and/or reduced lung
function in later life possible
Response to
treatment
Good response to ICS though not
disease modifying; good response to
bronchodilators
No response to ICS; poor
response to bronchodilators
Poor response to ICS; bronchodilators
can help
Abbreviations: BAL bronchoalveolar lavage; BDR bronchodilator response; BHR bronchial hyperresponsiveness; ETS environmental tobacco smoke; ICS inhaled
corticosteroids; LF lung function; NO nitric oxide; SPT skin prick test.
doi:10.1371/journal.pone.0008533.t002
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Our study suggests that there is wide agreement among
clinicians that preschool wheezing disorders consist of several
disease entities, but that there is less agreement as to how many
and which these are. Although a great diversity of specific disease
concepts exists there is much uncertainty regarding the biological
mechanisms that could justify them. A major problem is that the
clinical features observed in this young age group are not specific
for later disease course and physiological measurements are
difficult.
We propose a disease model for wheezing disorders in preschool
children comprising three entities linked to specific mechanisms: a)
allergic wheeze, b) non-allergic wheeze due to structural airway
narrowing and c) non-allergic wheeze due to increased immune
response to viral infections. Further research is needed to
determine whether or not these mechanisms are major causes of
wheezing in early childhood. The proposed model may be useful
for designing future studies so that hypothesised mechanisms are
measured at the right time. Few epidemiological studies to date
have collected data prospectively and at frequent intervals on the
early development of atopic sensitisation (for instance [39]) or on
factors related to increased responsiveness to viral infections in
early life [4,30,40,41]. Prospective studies including repeated
measurements of lung mechanics and physiology during infancy
and childhood in representative cohorts of children are almost
entirely lacking. There is an urgent need to develop non-invasive
measurements of lung function that can be applied at all ages.
Only this will allow these hypothesised entities, assuming that they
do exist to be disentangled.
If confirmed, these different causes of wheezing may have
important implications for treatment. Wheeze due to structural
airway narrowing might be a self limited disease, the natural
course of which may not be influenced by treatment. These
children are likely to outgrow their symptoms as their airways
increase in size with growth. However, because relative differences
may persist throughout life, relapse may occur in later adulthood
as elastic recoil decreases and lung function declines. The greatest
potential for disease modification by treatment is certainly for
allergic wheeze, but also, potentially, for the hypothesised entity
‘‘non-allergic wheeze due to increased immune responses to viral
infections’’.
As our study has shown, there is a clear need for a
standardisation of phenotype definitions. Ultimately such a
classification should be based on an understanding of the
pathogenesis of different disease entities.
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